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Background: Lynch syndrome is a hereditary cancer predisposition syndrome caused by a mutation in one of the
DNA mismatch repair (MMR) genes. About 24% of the mutations identified in Lynch syndrome are missense
substitutions and the frequency of missense variants in MSH6 is the highest amongst these MMR genes. Because of
this high frequency, the genetic testing was not effectively used in MSH6 so far. We, therefore, developed CoDP
(Combination of the Different Properties), a bioinformatics tool to predict the impact of missense variants in MSH6.
Methods: We integrated the prediction results of three methods, namely MAPP, PolyPhen-2 and SIFT. Two other
structural properties, namely solvent accessibility and the change in the number of heavy atoms of amino acids in
the MSH6 protein, were further combined explicitly. MSH6 germline missense variants classified by their associated
clinical and molecular data were used to fit the parameters for the logistic regression model and to assess the
prediction. The performance of CoDP was compared with those of other conventional tools, namely MAPP, SIFT,
PolyPhen-2 and PON-MMR.
Results: A total of 294 germline missense variants were collected from the variant databases and literature. Of
them, 34 variants were available for the parameter training and the prediction performance test. We integrated the
prediction results of MAPP, PolyPhen-2 and SIFT, and two other structural properties, namely solvent accessibility
and the change in the number of heavy atoms of amino acids in the MSH6 protein, were further combined
explicitly. Variants data classified by their associated clinical and molecular data were used to fit the parameters for
the logistic regression model and to assess the prediction. The values of the positive predictive value (PPV), the
negative predictive value (NPV), sensitivity, specificity and accuracy of the tools were compared on the whole data
set. PPV of CoDP was 93.3% (14/15), NPV was 94.7% (18/19), specificity was 94.7% (18/19), sensitivity was 93.3%
(14/15) and accuracy was 94.1% (32/34). Area under the curve of CoDP was 0.954, that of MAPP for MSH6 was
0.919, of SIFT was 0.864 and of PolyPhen-2 HumVar was 0.819. The power to distinguish between pathogenic and
non-pathogenic variants of these methods was tested by Wilcoxon rank sum test (p < 8.9 × 10-6 for CoDP,
p < 3.3 × 10-5 for MAPP, p < 3.1 × 10-4 for SIFT and p < 1.2 × 10-3 for PolyPhen-2 HumVar), and CoDP was shown
to outperform other conventional methods.
Conclusion: In this paper, we provide a human curated data set for MSH6 missense variants, and CoDP, the
prediction tool, which achieved better accuracy for predicting the impact of missense variants in MSH6 than any
other known tools. CoDP is available at http://cib.cf.ocha.ac.jp/CoDP/.
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Lynch syndrome (MIM: #120435, #609310), also known as
Hereditary Non-Polyposis Colorectal Cancer (HNPCC),
is an autosomal dominant disease and the most com-
mon hereditary colorectal cancer syndrome [1]. Lynch syn-
drome accounts for 1-5% of all colorectal cancer (CRC)
patients [2-4] and associates with germline mutations in
one of the DNA mismatch repair (MMR) genes including
MLH1, MSH2, MSH6 and PMS2 (MIM: #120436, #609
309, #600678, #600259, respectively). MMR gene mutation
carriers are at high risks of developing Lynch syndrome
associated cancer at colorectal, endometrial, small bowel,
stomach, ovary, ureter and hepatobiliary tract. Individuals
at high risks can be identified by the use of genetic testing,
and appropriate surveillance programs can be provided to
prevent cancer development.
Previous studies reported that more than 90% of the de-
tectable mutations in Lynch syndrome were found in
MLH1 and MSH2 [5]. Recent data, however, showed that
MSH6 contributed to about 20% of the mutations [6,7]. In
addition, MSH6 shows the greatest frequency (~37 - 49%)
of missense variants in the MMR genes, and most of them
are currently “unclassified variants” (UVs) [6,8].
MSH6 mutation carriers tend to develop CRC at the age
elder than MLH1 and MSH2 mutation carriers and tend to
show reduced penetrance [9-12]. These tendencies suggest
that family cancer history with an MSH6 mutation should
not be necessarily dense enough to meet the Amsterdam
criteria. Furthermore, colorectal tumor from MSH6 muta-
tion carriers sometimes demonstrates microsatellite in-
stability low (MSI-L) or microsatellite stable (MSS) [13], or
normal staining pattern of immunohistochemistry (IHC)
for MMR proteins [11]. It is, therefore, important to
analyze and integrate all the available data, and the data de-
rived from the use of in silico tools for the classification of
UVs is one of them.
A number of methods to predict the biological effects of
missense variants as pathogenic or genetic have been
reported. For Lynch syndrome, SIFT [14], PolyPhen
[15,16] and multivariate analysis of protein polymorphismsTable 1 Definition for classification of missense variants in M
LLS (Likely to be Lynch Syndrome):
Fulfill one or more of the following criteria;
1. Abnormal result of functional assay AND [abnormal IHC of only MSH6 OR MSI
2. Abnormal IHC of only MSH6 AND MSI-H
3. [Abnormal IHC of only MSH6 OR segregation analysis] AND fulfill
at least two of the following three criteria.
a) Family history: More than one affected relatives who were diagnosed as CRC or
endometrial cancer under 60 years old and at least in two successive generations
b) Proband‘s tumor feature: diagnosed as CRC or endometrial cancer under 50 ye
old and/or synchronous or asynchronous multiple cancers.
c) Control allele frequency = .00 (healthy population ≥ 100)(MAPP) [17] have been used in general. Predictions using
SIFT is based on sequence conservation, while that of
PolyPhen is based on sequence conservation plus protein
structural features [14-16]. These methods aim to predict
the pathogenicity of variants for general proteins and
hence they were not tuned to the interpretation of the pre-
diction for a specific protein. MAPP uses the evolutionary
variations and scales of six physicochemical properties to
evaluate the structural and functional impact of all possible
variants [17]. MAPP can be customized for a specific pro-
tein. It has been optimized to MLH1 and MSH2 and
outperformed SIFT and PolyPhen (MAPP-MMR [18]).
This result indicates that the algorithm customized for a
specific protein is superior to those applicable to proteins
in general. However, the accuracy of prediction by MAPP-
MMR is not satisfactory enough for the genetic testing.
Hence, improvement in the prediction method is required.
In the field of bioinformatics, especially the field for de-
veloping a prediction method out of amino acid sequences,
it has been pointed out that the prediction accuracy can be
improved by integrating many different prediction me-
thods (e.g. [19]). Following this idea, the accuracy of the
pathogenicity prediction could be improved by integrating
a number of existing methods to predict the biological ef-
fects of missense variants. In addition, none of the existing
methods directly incorporate the information obtained
from the MSH6 protein structure. The three-dimensional
structure of MSH6-MSH2 complex with ADP and DNA
was already solved [20]. The structural data should contain
varieties of information, some of which would be useful for
the prediction. The easily obtained information related to
the mutation effect to the structure includes the solvent ac-
cessibility of amino acid residue and the residue volume
change. The mutation of amino acid residue at the surface
of the protein are tolerant compared with that in the inter-
ior of the proteins, and a small volume change in amino
acid residues in mutation inside the protein is tolerant
compared with a mutation with a big volume change [21].
We, therefore, optimized MAPP [17] for MSH6 and then
integrated SIFT [14], PolyPhen-2 [15] and two propertiesSH6
ULS (Unlikely to be Lynch Syndrome):
Fulfill one or more of the following criteria;
-H] 1. Polymorphism (minor allele frequency ≥.01)
2. Normal result of functional assay AND [MSS OR normal IHC of MSH6]
3. MSS AND normal IHC of MSH6
.
ars
Figure 1 Domain organization of human MSH6 and the additional sequence set used for optimizing MAPP parameters for MSH6.
MSH6 protein is depicted by box diagram. A box indicates a distinct domain structure and a line connecting the boxes indicates an inter-domain
sequences. The range of the domain is shown above or beneath the box. “−” denotes non-vertebrate sequences in the secondary sequence set
added to the initial set. For the detail, see Optimization of MAPP for MSH6 section in Results and Discussion.
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volume change in amino acid residues. We joined these
properties on the logistic regression model and compared
the prediction performance with MAPP, SIFT, PolyPhen-2
and PON-MMR [22]. The parameter adjustment was done
on the data that we gathered from different databases and
literature and associated them with one another for this
study. The newly developed method achieved the best pre-
diction accuracy, sensitivity and specificity, and can distin-
guish pathogenic variants from non-pathogenic variants
clearly. We named the method CoDP, Combination of Dif-
ferent Properties on MSH6, and made it available at http://
cib.cf.ocha.ac.jp/CoDP/.
Methods
The dataset of MSH6 missense variants
MSH6 missense variants and their associated clinical
and molecular data were collected from the following
databases: InSiGHT (http://www.insight-group.org/), M
MRUV (http://www.mmrmissense.net/), UniProt (http://
www.uniprot.org/), dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/), NHLBI Exome Sequencing Project (ESP)
(http://evs.gs.washington.edu/EVS/), HapMap Project
(http://hapmap.ncbi.nlm.nih.gov/) and 1000 Genomes
(http://www.1000genomes.org/). A systematic literature
search was conducted on PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) to compile unregistered MSH6 mis-
sense variants in the databases above. These data were
used to assess the in silico pathogenicity prediction.
Clinical and molecular data on carriers with missense
variants were also collected. The data included the age at
the first diagnosis of CRC or endometrial cancer, any af-
fected relatives with Lynch syndrome associated cancer,
microsatellite instability (MSI), IHC, segregation study,
allele frequency and biochemical functional assay. The
biochemical functional assay included the investigations of
the following; MMR activity, MSH2 protein interaction,
localization, ATP hydrolysis and mismatch recognition.
We employed the results of the assay from the literature
as is. These clinical and molecular data were used to div-
ide the carriers into one of the following three categories;
“likely to be Lynch syndrome (LLS)”, “unlikely to be Lynch
syndrome (ULS)” and “unclassified.” LLS is a carrier with
pathogenic variant, and ULS is a carrier with non-
pathogenic variant. An “Unclassified” carrier has a variant
with unknown clinical significance, which is usually called
unclassified variant (UV). The division was carried out
based on the criteria shown in Table 1. When a carrier ful-
filled one or more of the criteria for LLS in Table 1, the
carrier was classified as LLS, and when a carrier fulfilled
one or more of the criteria for ULS, the carrier was classi-
fied as ULS. When the criterion that the carrier fulfilled
Terui et al. Journal of Biomedical Science 2013, 20:25 Page 4 of 13
http://www.jbiomedsci.com/content/20/1/25became important, a sub-numbering system was used,
such as LLS-1 for a carrier fulfilling the first criterion
of LLS.
Optimization of MAPP for MSH6
We optimized MAPP [17] to predict pathogenicity of
MSH6 missense variants. MAPP requires the appropriate
multiple sequence alignment of MSH6 orthologues for
evaluating missense variants. MSH6 amino acid sequences
were collected from GenBank (http://www.ncbi.nlm.nih.
gov/genbank/) using BLAST [23] by the default para-
meters and human MSH6 as a query sequence. The
sequences were also obtained from Ensembl genome data-
base (http://www.ensemblgenomes.org/). The inclusion of
both paralogous and orthologous sequences into the mul-
tiple sequence alignment for the training of MAPP was
known to worsen the performance of the prediction
[14,17]. We, therefore, selected orthologues of human
MSH6 sequences based on their domain organization and
a phylogenetic tree. There was a wide range of variability in
domain structures of the MSH6 proteins, and MSH6 se-
quences with the same domain organization to human
MSH6 are the good candidates of orthologues. Vertebrate
MSH6, the close homologues to human MSH6, generally
have a PCNA-binding motif [24], a PWWP domain [25]
and an MutS domain [20] (Figure 1). These vertebrate
MSH6 sequences were aligned together with other MSH6
homologs by T-Coffee alignment tool [26] and a phylogen-
etic tree was built. This phylogenetic tree was compared
with the species tree, and the proteins orthologous to hu-
man MSH6 were operationally defined by the sequences
with the same domain organization that located around the
human MSH6 consistently with the species tree. As a re-
sult, the vertebrate sequences were selected as an initial set
and a multiple sequence alignment of them was built for
MAPP prediction.
We then improved the prediction accuracy by increas-
ing the size of the sequence set. An augmented data set
was reported to improve the accuracy of the prediction
[18]. The addition of amino acid sequences to the data
set was limited to the domain regions, because the inter-Table 2 Variants classified as “Likely to be Lynch syndrome”










1 G566R 1 Inconclusive Normal ND Abnorm
2 R976H 1,2 ND Normal ND ND
3 G1139S 1,2 ND ND ND Abnorm
4 S1188N 1,2 Abnormal ND ND ND
5 E1193K 1,2 Abnormal Abnormal ND ND
Abbreviations: ND, Not done, H, MSI-high.
a See Table 1.domain sequences were too diverse to align. Sequences
of non-vertebrates were added to the initial sequence set
and the prediction accuracy was tested using a receiver
operating characteristic (ROC) curve and the area under
the curve (AUC).Structural properties to assess mutations in MSH6
Structural property for amino acid residue substitutions
was obtained on the three-dimensional structure of
MSH6-MSH2-DNA-ADP complex, registered as 2o8b [20]
in Protein Data Bank [27]. The registered structure is void
of residues at 551, 652, 942, and 992, and of loops at 720–
728, 1099–1104, 1123–1125, 1179–1187 and 1271–1283.
These missing structures were complemented using MOE
(Chemical Computing Group Inc. Montreal, Canada), mo-
lecular structure building software.
Two properties we focused on were relative accessible
surface area (accessibility) of each residue and the change
of volumes in residues by substitution. The accessible
surface area was calculated using a modified method of
Shrake and Rupley [28] with water radius of 1.4 Å [29].
The threshold of 0.1 was used to separate the locations
of residues into two categories; buried and surface. The
relevance of accessibility to the prediction was tested
based on the correlation between the accessibility and
LLS/ULS. The change of volumes was quantified by the
difference of the number of heavy atoms in the side
chains. The relevance of this value to the prediction was
also tested by the method that was the same as the one
used for the accessibility test.Combining different properties
We used the logistic regression model to integrate the
properties. The logistic regression analysis gives the prob-
ability (q) of a categorical variable outcome based on one
or more predictor variables (Xi). The logistic regression
equation is given by: logit(q) = ln [q/(1−q)] = Z + ∑biXi,
where Z is the constant and b1, b2, …, bn are the partial
correlation coefficients for X1, X2, …, Xn. We defined the





recognition MLH1 MSH2 MSH6
al ND ND ND ND H [12,30-32]
Abnormal Normal Normal Abnormal H [30,33]
al ND Normal Inconclusive Abnormal H [34-36]
ND Normal Normal Abnormal H [38]
ND Normal Inconclusive Abnormal H [31,37]
Table 3 Variants classified as LLS without functional assay
No. Variant Definitionof LLSa
IHC
MSI Segregationstudy FH PTF
Healthy control =0
(N>100) ReferencesMLH1 MSH2 MSH6
6 L449P 2,3 Normal Normal Abnormal H ND Abnormal Abnormal ND [39]
7 C559Y 3 ND ND ND ND Abnormal Abnormal Abnormal ND [44]
8 P591S 2,3 Normal Normal Abnormal H ND Abnormal Abnormal Abnormal [40]
9 P623L 3 Normal Normal Abnormal L ND Normal Abnormal Abnormal [31]
10 G670R 2 Normal Normal Abnormal H ND Normal Normal ND [41]
11 R772W 2 Normal Normal Abnormal H ND Normal Normal Inconclusive (0/95) [42]
12 Y969C 2,3 Normal Normal Abnormal H Abnormal Abnormal Abnormal Inconclusiveb [43,44]
13 G1069E 2 Normal Normal Abnormal H ND Normal Normal ND [45]
14 R1076C 3 Normal Normal Abnormal ND ND Abnormal Abnormal ND [47,48]
15 A1236P 2,3 Normal Normal Abnormal H ND Abnormal NA Abnormal [46]
Abbreviations: ND, not done, H, MSI-high, L, MSI-low.
a See Table 1.
b The number of healthy population is unknown.
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MSH6, SIFT, PolyPhen-2 and the appropriate structural
properties discussed above were used as predictors Xi.
Variant sets of LLS and ULS without the biochemical
functional assay were used to optimize bi. The applicabil-
ity of the joint score for prediction was tested on the
variants of LLS and ULS with the biochemical functio-
nal assay.
Performance test
The capability of predicting the impact of UVs was tested
using the variants of LLS and ULS. The prediction per-
formance of the tools, CoDP, MAPP for MSH6, SIFT,
PolyPhen-2 and PON-MMR, was compared. The com-
parison was carried out on prediction score distributions.
The positive predictive value (PPV), the negative
predictive value (NPV), sensitivity, specificity and accur-
acy were calculated as follows: PPV = TP / (TP + FP);
NPV = TN / (FN+TN); Sensitivity = TP / (TP+FN);
Specificity = TN / (FP+TN); Accuracy = (TP+TN) /
(TP +TN+FP+FN), where TP is true positive, FP is false
positive, TN is true negative and FN is false negative. To
classify pathogenic variants, the threshold values 0.05
and 0.446 were used in SIFT [14] and PolyPhen-2 [15],














16 R128L 2 NA Normal Normal ND ND
17 S1441 2,3 <0.01 Normal Normal ND ND
18 L396V 1,2 ≥0.01 Normal ND ND ND
19 K728T 2,3 NA Normal Normal ND ND
Abbreviations: NA, Not available, ND, Not done; H, MSI-high; L, MSI-low; S; Microsate
a See Table 1.compared using AUC. The box and whisker plot for each
prediction was drawn to clarify the power to distinguish
between LLS and ULS variants. Statistical analyses were
carried out on PASW Statistics 18.0.0 software program
(SPSS Inc., Chicago, IL, USA).
Results and discussion
The dataset of MSH6 germline missense variants
A total of 294 germline missense variants were collected
from the variant databases and literature (Additional file 1:
Table S1). Pathogenicity of these variants was determined
based on the molecular and clinical data, and the variants
were classified into three categories, namely LLS, ULS and
UV (Table 1). Out of these 294 variants data, fifteen were
classified as LLS (Tables 2 and 3) and nineteen as ULS
(Tables 4 and 5).
Out of fifteen LLS variants, five variants including
G566R, R976H, G1139S, S1188N and E1193K showed ab-
normality in protein function assay (Table 2). These five
variants also showed high level of MSI (MSI-H), and
showed loss of MSH6 expression except for G566R variant
[12,30-38]. Hence, these five variants were LLS-1 and/or
LLS-2. Out of the remaining ten LLS variants (=15-5),
L449P, P591S, G670G, R772W, Y969C, G1069E and






ND Abnormal Normal Normal H [31]
ND Normal Normal Normal S [30,49,50]
ND Normal Normal Normal L/H [32,34]
ND Abnormal Abnormal Abnormal S [31]
llite stable.
Table 5 Variants classified as ULS showing polymorphism or normal IHC and MSS
No Variant Definition of ULSa Polymorphism MLH1 MSH2 MSH6 MSI References
20 K13T 3 <0.01 Normal Normal Normal S [49]
21 A25V 1 ≥0.01 ND ND ND ND db S NP, 1000 Genomes
22 G39E 1 ≥0.01 ND ND ND ND db S NP, 1000 Genomes
23 G54A 3 NA Normal Normal Normal S [51]
24 S65L 3 <0.01 Normal Normal Normal S [49]
25 C196F 1 ≥0.01 ND ND ND ND db S NP, 1000 Genomes
26 R468H 3 <0.01 Normal Normal Normal S [49]
27 S503C 3 <0.01 Normal Normal Normal S [49]
28 R635G 3 NA Normal Normal Normal S [52]
29 l886V 1 ≥0.01 ND ND ND ND 1000 Genomes
30 l1054F 3 NA Normal Normal Normal S [34]
31 E1163V 1 ≥0.01 ND ND ND ND 1000 Genomes
32 E1196K 1 ≥0.01 ND ND ND ND db S NP 1000 Genomes
33 E1234Q 1 ≥0.01 ND ND ND ND db S NP 1000 Genomes
34 E1304K 1 ≥0.01 ND ND ND ND 1000 Genomes
Abbreviations: NA; Not available, ND, Not done, S, Microsatellite stable.
a See Table 1.
Figure 2 The number of changes in heavy atoms between the
original and the substituted amino acid. For instance, in change
0–1 (no or one change in the number of heavy atoms by
substitution), the cases of ULS are more frequent than those of LLS.
An I-form line on each bar denotes a standard deviation obtained
by the bootstrap method with 1,000 resampling. The distributions
do not overlap in the number of changes 0–1 and 2–3.
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clinical criteria, such as family cancer history and pro-
bands’ tumor features [39-46], and hence these seven vari-
ants were LLS-2 and/or LLS-3 (Table 3). The remaining
three LLS variants (=15-5-7), namely C559Y, P623L and
R1076C, were LLS-3 [31,44,47,48] (Table 3).
Out of nineteen ULS variants, four variants including
R128L, S144I, L396V and K728T showed normal function
in protein function assay and normal staining pattern in
IHC, hence fulfilled definition ULS-2 [30-32,34,49,50]
(Table 4). In addition, L396V was polymorphism and
also fulfilled definition ULS-1. Out of the remaining fif-
teen ULS variants (=19-4), K13T, G54A, S56L, R468H,
S503C, R635G and I1054F variants demonstrated MSS
and showed normal expression of MSH6 [34,49,51,52],
hence these seven variants possessed normal MMR ac-
tivity and fulfilled definition ULS-3 (Table 5). The
remaining eight (=19-4-7) ULS variants, namely A25V,
G39E, C196F, I886V, E1163V, E1196K, E1234Q and
E1304K were polymorphism and fulfilled definition
ULS-1 (Table 5).
In total, 34 variants in Tables 2, 3, 4 and 5 were available
for prediction assessment, and the remaining 260 variants,
which were UVs, were the targets to predict whether
each of them was either LLS or ULS. In the following ana-
lyses, we used the data in Tables 3 and 5 as a parameter
training data set, and the data in Tables 2 and 4 as a pre-
diction test data set. All 34 variants data was referred to as
the whole data set. And we applied the prediction to UV
dataset at the end.
Table 6 Prediction performance of in silico tools in the whole data set
CoDP MAPP for MSH6 SIFT PolyPhen2 HumVar PolyPhen2 HumDiv
TP 14 14 10 14 14
TN 18 17 15 10 8
FP 1 1 4 9 11
FN 1 2 5 1 1
PP0V 0.933 (14/15) 0.875 (14/16) 0.714 (10/14) 0.609 (14/23) 0.560 (14/25)
NPV 0.947 (18/19) 0.944 (17/18) 0.750 (15/20) 0.909 (10/11) 0.889 (8/9)
Sencitivity 0.933 (14/15) 0.875 (14/15) 0.667 (10/15) 0.933 (14/15) 0.933 (14/15)
Specificity 0.941 (32/34) 0.912 (31/34) 0.735 (25/34) 0.706 (24/34) 0.647 (22/34)
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The sequence data set for the multiple alignments
From GenBank and Ensembl, 126 sequences of MSH6
orthologues were selected (Additional file 2: Table S2). Of
them, 34 were derived from vertebrates. Most of the verte-
brate orthologues had, from the N-terminus, a PCNA-
binding motif (Qxx[LI]xx[FF], amino acid 4–11 in human
MSH6) [24], a PWWP domain (amino acid 89–194)
[25] and an MutS domain (amino acid 362–1355) [20]
(Figure 1). These sequences were a set of initial sequences
for a multiple sequence alignment.
We then added the amino acid sequences of the PCNA-
binding motif and of the PWWP domain of 91 non-
vertebrate MSH6 to the initial set, and found that the
prediction performance was improved. The procedure of
adding more amino acid sequences of MutS domain was,
however, not straightforward. Three different sets of se-
quences were made from the non-vertebrate MutS domain.
The first set contained the entire non-vertebrate MutS do-
main (91 sequences). The second set contained MutS do-
mains derived from the sequences that were comprised of
both the MutS and PWWP domains (5 sequences). The
third set contained MutS domains derived from the se-
quences that were comprised of both the MutS domain
and PCNA-binding motif (58 sequences). A multiple se-
quence alignment was built with initial sequences plus each
of the described sequence sets, and the performance of pre-
diction was tested on the whole data set using an ROC
curve. The AUC of the first set was 0.767, that of the sec-
ond set was 0.689 and that of the third set was 0.811. It
turned out that the initial set plus the third set, namely se-
quences of both MutS domain and PCNA-binding motif,
performed best and this set was used hereafter.
Normalization of the impact score
MAPP determines the pathogenicity of missense variants
by an index known as impact score. The threshold of the
impact score is required to determine whether the variant
is pathogenic or not. The impact score basically depends
on the degree of conservation of amino acid types in the
alignment position [17]. Therefore, the threshold of theimpact score in different domains of MSH6 likely varies.
Indeed, the optimum threshold for the initial sequence set
was 8.5, that for the PCNA-binding motif was 4.1, that for
the PWWP domain was 5.0 and that for the MutS domain
was 4.1. The different threshold values of the different do-
mains in the same sequence could cause confusion. We,
therefore, normalized the impact scores so as to make the
threshold value 1.0 throughout the sequence.
The prediction performance of MAPP for MSH6
This type of prediction method should ideally distin-
guish disease-causing variants from benign variants [53].
The distributions of the score of MAPP for MSH6 be-
tween LLS and ULS variants in the whole data set were
significantly different. The average for LLS and ULS was
2.673 and 0.851, respectively (Student’s t-test: p < .001)
and median for LLS and ULS was 2.099 and 0.770, re-
spectively (Mann–Whitney U test: p < .001). The cap-
ability of this tool is, therefore, reasonably sufficient
to distinguish pathogenic variants from non-pathogenic
variants.
Development of CoDP
The prediction performance of SIFT and PolyPhen-2
We examined the prediction performance of both SIFT
and PolyPhen-2 on the whole data set. PolyPhen-2 calcu-
lates values of both HumDiv and HumVar. HumDiv is
used for diagnosis of Mendelian disease, and HumVar is
used for the evaluation of rare alleles potentially involved
in complex phenotypes [15]. Both SIFT and PolyPhen-2
clearly distinguished the median for LLS variants and
that for ULS variants (Mann–Whitney U test: HumVar
p < .001, HumDiv p < .001, SIFT p < .001).
Correlation between the structural properties of the MSH6
protein and LLS/ULS
The correlation between solvent accessibility of sub-
stituted amino acid and LLS/ULS was found to be statis-
tically significant. The average of the solvent accessibility
of the substituted amino acid residues in LLS and in
ULS variants were 0.141 and 0.589, respectively
Figure 3 Box and whisker plots for distributions of prediction scores of in silico tools in LLS and ULS variants. The top and the bottom
of the box are the 75th and 25th percentile, respectively, and the black line in the box is the median. × denotes an outlier. The distributions of
LLS and ULS in CoDP (a) are better separated than those of MAPP for MSH6 (b), SIFT (c) and PolyPhen-2 (d).
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accessibility of the residues in LLS and ULS variants
were 0.087 and 0.583, respectively (Mann–Whitney U
test:
p < .005). The amino acid residues substituted in LLS
tend to have smaller accessibility than those in ULS vari-
ants. Similarly, the correlation between the changes in
the number of heavy atoms in the side chains of the
substituted residues in LLS/ULS variants was also sig-
nificant (Figure 2). Minor change in the number of
heavy atoms in the side chains was often observed in
ULS. These significant differences in the two properties
evidently have a potential to be used as predictors for
pathogenicity of MSH6 variants. When these two prop-
erties alone were applied to the whole data set, eleven
out of 15 LLS variants and 17 out of 19 ULS variants
were correctly distinguished, which is equivalent to
82.4% accuracy, using the most appropriate threshold. It
is surprising to find that this simple and explicit usage








TP 5 4 4 5 5
TN 4 4 4 2 1
FP 0 0 0 2 3
FN 0 1 1 0 0
PPV 5/5 4/4 4/4 5/7 5/8
NPV 4/4 4/5 4/5 2/2 1/0
Sencitivity 5/5 4/5 4/5 5/5 5/5
Specificity 4/4 4/4 4/4 2/4 1/4
Accuracy 9/9 8/9 8/9 7/9 6/9sification power comparable to the power of SIFT and
PolyPhen2.
Combining different properties by logistic regression model
To further improve the prediction accuracy, we combined
different prediction methods above on the logistic regres-
sion equation and the weight for each method was opti-
mized using the training data set. The logistic regression
equation for joint score q was obtained as:
logit qð Þ ¼ ln q= 1−qð Þ½ 
¼ –3:7273
þ0:1581 the impact score of MAPP for MSH6
–1:2824 the SIFT score
þ 4:6733 the PolyPhen−2 HumVarð Þ score
þ 1:0475 the number of Δ heavy atoms of side chainsj j
–8:0548 the accessibility
The significance level is less than 1% and hence this
model seems to be useful for the prediction. In the equa-
tion above, we omitted PolyPhen-2 HumDiv, because
HumDiv had low accuracy, as will be explained below.
We calculated both AUC and the cut-off value of joint
score q. AUC was 0.954 and the cut-off value was 0.56.
Based on these values, we considered that the variants
with the joint score q = 0.56 or less has minor impact on
the function of the MSH6 protein, and hence the variants
were likely to be non-pathogenic variants. The variants
with the joint score q more than 0.56 were, therefore,
likely to be pathogenic. More specifically, the variants
with the joint score q more than 0.65 likely have the
function impaired. And the variants with the joint score
q between 0.56 and 0.65 likely have moderate impact on
Table 8 Classification results of UVs in MSH6 by CoDP
The variants with no impact on MSH6 The variants with moderate impact on MSH6 The variants with impact on MSH6
Variants Score Variants Score Variants Score Variants Score Variants Score Variants Score
S9G 0.000 S360I 0.000 L815I 0.180 G670V 0.595 L370S 0.832 A1021D 0.988
A20V 0.000 R361H 0.000 P831A 0.060 S1049F 0.572 Y397C 0.976 R1024W 0.938
A20D 0.000 T369I 0.009 D857N 0.426 I1227L 0.619 L435P 0.942 D1026Y 0.995
N21S 0.000 E381K 0.001 V867G 0.189 A457P 0.951 D1031V 0.722
A25S 0.000 D390N 0.003 V878A 0.009 R468C 0.992 R1034Q 0.724
A36V 0.000 Y397F 0.003 D880E 0.000 V474A 0.930 A1055T 0.935
P42S 0.000 I425V 0.115 Q889H 0.022 V480L 0.853 D1058S 0.975
W50R 0.000 I442T 0.017 I891M 0.031 E484K 0.826 V1059A 0.716
A81T 0.000 E446N 0.027 L893V 0.016 V509A 0.969 A1064V 0.846
A81V 0.000 N455T 0.000 R901H 0.035 I516N 0.740 Y1066C 0.999
K99N 0.003 Q475H 0.261 D904E 0.006 T521I 0.911 P1087H 0.978
I120V 0.000 K476E 0.145 V907A 0.001 Y535C 0.894 P1087R 0.995
E122K 0.000 M492V 0.530 E983Q 0.074 Y538S 0.998 R1095H 0.692
K125E 0.000 R497T 0.028 N984H 0.006 D575Y 0.997 R1095C 0.996
L147H 0.000 K498R 0.000 F985L 0.016 S580L 0.997 T1100R 0.860
A159V 0.000 Q522R 0.097 R988L 0.017 P656L 0.943 I1115T 0.802
H164P 0.000 P531T 0.003 P991L 0.065 S682C 0.653 T1142M 0.864
K185E 0.000 E533D 0.006 T1008I 0.302 S682F 0.998 G1148R 1.000
K187T 0.000 E546G 0.031 R1024Q 0.053 G685A 0.939 G1157S 0.964
E192V 0.000 E546Q 0.003 Q1048E 0.002 L700F 0.985 A1162P 0.970
V195F 0.015 S549F 0.468 V1056M 0.360 S702G 0.951 T1175S 0.822
D197H 0.001 Y556F 0.162 R1068G 0.312 F706S 0.996 E1187G 0.998
E198A 0.000 I570V 0.054 P1073S 0.001 R761G 0.922 L1201F 0.984
P202A 0.000 R577H 0.522 P1073R 0.042 C765W 1.000 D1213V 0.932
M208V 0.000 F582L 0.146 V1078A 0.004 G770V 0.994 E1214A 0.992
V210A 0.000 I608V 0.033 P1082S 0.018 R772Q 0.954 R1217K 0.880
V215I 0.000 K610N 0.009 P1082L 0.012 W777R 0.994 T1219I 0.944
D217Y 0.001 E619D 0.291 P1087T 0.056 A780G 0.713 T1225M 0.888
E220D 0.000 P623A 0.010 P1087S 0.201 I795T 0.707 R1242L 0.966
E221D 0.000 G624S 0.072 E1090K 0.007 L798V 0.919 T1243S 0.650
N223D 0.000 E639K 0.005 T1100M 0.025 Y850C 1.000 V1253E 0.856
N223S 0.000 R644S 0.057 K1101N 0.002 K854M 0.826 R1263C 0.767
S227I 0.000 K646R 0.223 P1110S 0.376 S860F 0.982 R1263H 0.669
E229G 0.008 I651T 0.000 I1113T 0.045 K866T 0.685 M1267T 0.946
P233R 0.000 M654I 0.001 E1121D 0.000 Q889P 0.682 C1275Y 0.992
R243C 0.005 S666P 0.008 A1151V 0.055 L909S 0.967 T1284M 0.913
R243H 0.000 D667H 0.453 V1160I 0.117 D943Y 0.900 A1303T 0.981
I245L 0.000 I669T 0.000 D1181E 0.540 Y977H 0.945 A1303G 0.916
I251V 0.000 P673A 0.405 M1202V 0.009 R988C 0.716 R1321G 0.825
I258T 0.000 E675D 0.000 V1232L 0.318 Y994H 0.895 L1353W 0.989
F265C 0.119 K676R 0.006 H1248D 0.022 S998T 0.853
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Table 8 Classification results of UVs in MSH6 by CoDP (Continued)
T269S 0.000 Q698K 0.005 V1253L 0.068
K270M 0.001 Q698E 0.006 V1260I 0.001
E277D 0.000 A704G 0.008 N1273S 0.008
S285I 0.000 T719I 0.006 E1274K 0.006
G289D 0.000 T720A 0.033 S1279P 0.014
G289E 0.000 T720I 0.024 I1283V 0.001
K295E 0.000 I725M 0.000 E1310D 0.001
K295R 0.001 I725V 0.000 E1311D 0.004
R300P 0.001 F726S 0.208 R1321S 0.128
S314I 0.000 R761K 0.015 M1326I 0.001
S314R 0.001 T764N 0.005 M1326T 0.002
S315F 0.003 P768A 0.201 S1329L 0.014
T319M 0.000 C783S 0.409 R1331L 0.011
P320T 0.000 A787V 0.063 R1334Q 0.000
A326V 0.000 V800L 0.000 D1346N 0.001
T327S 0.000 V800A 0.000 L1354Q 0.018
F340S 0.001 D803G 0.003 K1358E 0.001
S360G 0.000 S806F 0.450
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test data set, namely the variants with the biochemical
functional assay (Tables 2 and 4), and found that the pro-
cedure predicted those variants correctly (LLS: 5/5 vari-
ants, ULS: 4/4 variants). Of the five LLS variants, four
variants, namely G566R, G1139K, S1188N and E1193K,
were in the category of “impaired function. ”
Comparison of prediction performance
The performance of CoDP was first compared with those
of other conventional tools, namely MAPP, SIFT, Po-
lyPhen-2 and PON-MMR on the whole data set. The
values of PPV, NPV, sensitivity, specificity and accuracy
were compared (Table 6). PPV of CoDP was 93.3% (14/15),
NPV was 94.7% (18/19), sensitivity was 93.3% (14/15), spe-
cificity was 94.7% (18/19) and accuracy was 94.1% (32/34).
All these scores were better than those of the conventional
methods except for PON-MMR. PON-MMR predicted
eleven out of 34 LLS/ULS variants as either pathogenic or
non-pathogenic variants, and remaining 23 variants as
UVs. The eleven variants were predicted correctly, of
which three were pathogenic variants and eight were non-
pathogenic variants. However, prediction by PON-MMR
did not classify 23 (= 34–11) variants as pathogenic or
non-pathogenic, and hence the method cannot be used for
UV curation, which we aim for in our tools. Therefore, we
put PON-MMR aside in this comparison. Superiority of
CoDP was also clarified by AUC. AUC of CoDP was 0.954,
that of MAPP for MSH6 was 0.919, of SIFT was 0.864 and
of PolyPhen-2 HumVar was 0.819. The power todistinguish between LLS and ULS of these methods was vi-
sualized by the box and whisker plot (Figure 3) and further
tested by Wilcoxon rank sum test. The test ended in
p < 8.9 × 10-6 for CoDP, p < 3.3 × 10-5 for MAPP, p < 3.1 ×
10-4 for SIFT and p < 1.2 × 10-3 for PolyPhen-2 HumVar.
These tests clearly demonstrated that CoDP outperformed
other conventional methods.
When the performances of the tools were compared on
the test data set alone, only CoDP predicted all test vari-
ants correctly. The values of PPV, NPV, sensitivity, specifi-
city and accuracy of the tools in the test data set were
shown in Table 7 (MAPP LLS: 4/5 variants, ULS: 4/4 vari-
ants; SIFT LLS: 4/5 variants, ULS: 4/4 variants; PolyPhen-2
HumVar LLS: 5/5 variants, ULS: 2/4 variants). AUC of
CoDP was 1.000, that of MAPP for MSH6 was 0.800, of
SIFT was 0.950 and of PolyPhen-2 HumVar was 0.900.
The power to distinguish between LLS and ULS of these
methods on the test data set was p < 1.5 × 10-2 for CoDP,
p < 1.9 × 10-1 for MAPP, p < 6.5 × 10-2 for SIFT and
p < 1.5 × 10-2 for PolyPhen-2 HumVar. The box and whis-
ker plot that visualized the distribution of the scores were
shown in Additional file 3: Figure S1.
The small size of the test data set may raise doubts on
the superiority of CoDP. To overcome the paucity of the
test sample, we also employed a leave-one-out jackknife
method and evaluated the performance of the tools. CoDP
predicted 85.3% (29/34, LLS 93.3%, 14/15, ULS 78.9%, 15/
19) of the variants correctly and the performance was still
better than SIFT and PolyPhen-2 HumVar (Table 6). Here,
we did not compared the performance of CoDP and
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on the information retrieved from the homologous se-
quences and hence it was difficult to leave the information
of the target sequence out of the training set.
Predicting UVs by CoDP
We now used CoDP to interpret 260 germline missense
variants, which were classified as UVs. Of 260 UVs, 84
variants (32.3%) were predicted as pathogenic variants, and
176 variants (67.7%) as non-pathogenic variants, hence
about one third of the UVs detected in MSH6 were
predicted as pathogenic variants. Of these putative 84
pathogenic variants, three variants were predicted to have
the moderate impact on the protein (0.56 < joint score
q ≤ 0.65), and the 81 variants were predicted to have
impaired function (joint score q > 0.65) (Table 8).
The higher joint scores of CoDP tend to derive from the
mutations in the conserved domain, namely in the MutS
domain. This tendency suggests that missense mutations in
the domain should have considerable influence on protein
function. The MutS domain in MSH6 forms a heterodimer
with MSH2 and participates in the early recognition of mis-
matches and small insertion/deletion loops of DNA [54,55].
For instance, the E1193K variant, classified as LLS, is lo-
cated in the MutS domain V region (Figure 1). The MutS
domain V region is the highly conserved region in MutS
homologues [20]. This variant showed remarkable impair-
ment of function, such as the loss of heterodimerization
with MSH2 and MMR activity [31]. CoDP gave the joint
score q = 0.813 to E1193K variant, indicating that the vari-
ant likely has significant damage to the structure of MSH6,
which may impair the function of the protein.
Conclusion
In this study, we built CoDP, the new prediction tool to as-
sess the MSH6 missense variants. The novelty of CoDP lies
in the direct incorporation of protein three-dimensional
structure information and the introduction of the logistic
regression model for combining the different prediction
methods. The former feature was found to have unexpect-
edly high performance in LLS/ULS classification, and the
latter procedure can be interpreted as an introduction of a
simple neural network model for combining outputs from
different prediction schemes. These new features enabled
CoDP to achieve better performance for the classification
of the MSH6 variants. The better performance was also
sustained by the manually curated dataset of MSH6 vari-
ants presented in Tables 2, 3, 4, 5, and 6.
For adjusting the parameters, we carefully categorized
MSH6 germline missense variants into LLS and ULS. In
the current dataset, only 34 out of 294 variants could be
categorized into LLS and ULS. This was due to the paucity
of both biochemical functional assay data and clinical and
molecular data that are linked to the variants of MSH6 onthe databases. This data paucity makes the present CoDP
not be clinically applicable. However, current form of CoDP
has better utility for supporting a risk estimation of UVs in
MSH6, as SIFT or PolyPhen-2 does to other proteins. In
the future when more associated data would be obtained,
the appropriate parameters would be set, and the accuracy
of CoDP would be further improved.
Additional files
Additional file 1: Table S1. MSH6 missense variants data used for
parameter fitting. The file can be read by standard TIF viewer, such as
Preview on Mac OS X.
Additional file 2: Table S2. A list of amino acid sequences used for the
multiple sequence alignment of MSH6. The file can be read by standard
TIF viewer, such as Preview on Mac OS X.
Additional file 3: Figure S1. Box and whisker plots for the score
distribution of in silico tools evaluated on the test set. The top and the
bottom of the box are the 75th and 25th percentile, respectively, and the
white line in the box is the median. The distributions of LLS and ULS are
divided clearly. The file can be read by standard TIF viewer, such as
Preview on Mac OS X.
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